Conquer the key step of Alzheimers disease! The new drug completes the phase 3 clinical trial.

category:Society
 Conquer the key step of Alzheimers disease! The new drug completes the phase 3 clinical trial.


Alzheimers disease, commonly known as Alzheimers disease, is characterized by progressive loss of cognitive function in the brain. According to the international Alzheimers Association, there are about 48 million patients worldwide.

The 3 phase of the clinical trial of GV-971 was a randomized, double-blind, placebo controlled 36 week study in China to assess the effectiveness and safety of GV-971 in patients with mild to moderate Alzheimers disease (the simple mental state examination scale score of 11-26). During the clinical study, the patients took 450 mg of oral medicine, two times a day. The main efficacy end point was the change in the cognitive part of Alzheimers disease rating scale after 36 weeks. The results showed that GV-971 achieved the expected effect on cognitive function improvement, and had significant statistical significance and clinical significance. The incidence of adverse events was very similar to that of placebo. In particular, no side effects of abnormal amyloid associated imaging were found.

The drug is a marine oligosaccharide molecule extracted from seaweed. Unlike traditional targeted antibody drugs, GV-971 can capture beta amyloid (A beta) in multiple points, segments and multistates, inhibit the formation of A beta fibrils and depolymerization the formed fibrils into nontoxic monomers. The latest research has found that GV-971 also prevents the progression of Alzheimers disease by regulating the imbalance of intestinal flora and remodeling the immune homeostasis of the body, thereby reducing neuroinflammation in the brain. The leader of the R & D team said that the 3 positive results of the GV-971 clinical period were the crystallization of the teams 21 year struggle. The early R & D was derived from the China Sea, and the further development was completed by the Shanghai Institute of Materia Medica and the Green Valley pharmaceutical. GV-971s novel mode of action and unique multi target characteristics have opened up a new path for the development of Alzheimers disease, and it is hopeful to lead the new wave of research and development of carbohydrates, which is of profound significance to the promotion of the international status of the research field of innovative drugs in China. It is reported that the Shanghai Green Valley pharmaceutical will submit to the national drug supervision and Administration Bureau in accordance with the process in accordance with the process. The GV-971 application for the treatment of mild and moderate Alzheimers disease will be submitted in the year. Source: Xinhua editor: Qian Yue Xiao _NBJ10675

The leader of the R & D team said that the 3 positive results of the GV-971 clinical period were the crystallization of the teams 21 year struggle. The early R & D was derived from the China Sea, and the further development was completed by the Shanghai Institute of Materia Medica and the Green Valley pharmaceutical. GV-971s novel mode of action and unique multi target characteristics have opened up a new path for the development of Alzheimers disease, and it is hopeful to lead the new wave of research and development of carbohydrates, which is of profound significance to the promotion of the international status of the research field of innovative drugs in China.

It is reported that the Shanghai Green Valley pharmaceutical will submit to the national drug supervision and Administration Bureau in accordance with the process in accordance with the process. The GV-971 application for the treatment of mild and moderate Alzheimers disease will be submitted in the year.